Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Hernandez DG, Reed X, Singleton AB.

J Neurochem. 2016 Oct;139 Suppl 1:59-74. doi: 10.1111/jnc.13593. Epub 2016 Apr 18. Review.

2.

LRRK2 G2385R and R1628P mutations are associated with an increased risk of Parkinson's disease in the Malaysian population.

Gopalai AA, Lim SY, Chua JY, Tey S, Lim TT, Mohamed Ibrahim N, Tan AH, Eow GB, Abdul Aziz Z, Puvanarajah SD, Viswanathan S, Looi I, Lim SK, Tan LP, Chong YB, Tan CT, Zhao Y, Tan EK, Ahmad-Annuar A.

Biomed Res Int. 2014;2014:867321. doi: 10.1155/2014/867321. Epub 2014 Aug 28.

3.

Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications.

Rudenko IN, Cookson MR.

Neurotherapeutics. 2014 Oct;11(4):738-50. doi: 10.1007/s13311-014-0284-z. Review.

4.

Leucine-rich repeat kinase 2-linked Parkinson's disease: clinical and molecular findings.

Kumari U, Tan EK.

J Mov Disord. 2010 Oct;3(2):25-31. doi: 10.14802/jmd.10008. Epub 2010 Oct 30. Review.

5.

Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain.

Piccoli G, Onofri F, Cirnaru MD, Kaiser CJ, Jagtap P, Kastenmüller A, Pischedda F, Marte A, von Zweydorf F, Vogt A, Giesert F, Pan L, Antonucci F, Kiel C, Zhang M, Weinkauf S, Sattler M, Sala C, Matteoli M, Ueffing M, Gloeckner CJ.

Mol Cell Biol. 2014 Jun;34(12):2147-61. doi: 10.1128/MCB.00914-13. Epub 2014 Mar 31.

6.

Genetic variants ofLRRK2 in Taiwanese Parkinson's disease.

Wu YR, Chang KH, Chang WT, Hsiao YC, Hsu HC, Jiang PR, Chen YC, Chao CY, Chang YC, Lee BH, Hu FJ, Chen WL, Lee-Chen GJ, Chen CM.

PLoS One. 2013 Dec 5;8(12):e82001. doi: 10.1371/journal.pone.0082001. eCollection 2013.

7.

Patterns of linkage disequilibrium of LRRK2 across different races: implications for genetic association studies.

Li H, Teo YY, Tan EK.

PLoS One. 2013 Sep 5;8(9):e75041. doi: 10.1371/journal.pone.0075041. eCollection 2013.

8.

LRRK2: cause, risk, and mechanism.

Paisán-Ruiz C, Lewis PA, Singleton AB.

J Parkinsons Dis. 2013;3(2):85-103. doi: 10.3233/JPD-130192. Review.

9.

Non-motor and motor features in LRRK2 transgenic mice.

Bichler Z, Lim HC, Zeng L, Tan EK.

PLoS One. 2013 Jul 30;8(7):e70249. doi: 10.1371/journal.pone.0070249. Print 2013.

10.

Environmental-genetic interactions in the pathogenesis of Parkinson's disease.

Tsuboi Y.

Exp Neurobiol. 2012 Sep;21(3):123-8. doi: 10.5607/en.2012.21.3.123. Epub 2012 Sep 17.

11.

Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe.

Rubio JP, Topp S, Warren L, St Jean PL, Wegmann D, Kessner D, Novembre J, Shen J, Fraser D, Aponte J, Nangle K, Cardon LR, Ehm MG, Chissoe SL, Whittaker JC, Nelson MR, Mooser VE.

Hum Mutat. 2012 Jul;33(7):1087-98. doi: 10.1002/humu.22075. Epub 2012 Apr 4.

12.

Analysis of GWAS-linked loci in Parkinson disease reaffirms PARK16 as a susceptibility locus.

Tan EK, Kwok HH, Tan LC, Zhao WT, Prakash KM, Au WL, Pavanni R, Ng YY, Satake W, Zhao Y, Toda T, Liu JJ.

Neurology. 2010 Aug 10;75(6):508-12. doi: 10.1212/WNL.0b013e3181eccfcd. Erratum in: Neurology. 2010 Oct 12;75(15):1399. Kwok, H-K [corrected to Kwok, H-H].

13.

Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C.

Hum Mutat. 2010 Jul;31(7):763-80. doi: 10.1002/humu.21277. Review.

14.

Deletion of the WD40 domain of LRRK2 in Zebrafish causes Parkinsonism-like loss of neurons and locomotive defect.

Sheng D, Qu D, Kwok KH, Ng SS, Lim AY, Aw SS, Lee CW, Sung WK, Tan EK, Lufkin T, Jesuthasan S, Sinnakaruppan M, Liu J.

PLoS Genet. 2010 Apr 22;6(4):e1000914. doi: 10.1371/journal.pgen.1000914.

15.

The WD40 domain is required for LRRK2 neurotoxicity.

Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT.

PLoS One. 2009 Dec 24;4(12):e8463. doi: 10.1371/journal.pone.0008463.

16.
17.

LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease.

Zabetian CP, Yamamoto M, Lopez AN, Ujike H, Mata IF, Izumi Y, Kaji R, Maruyama H, Morino H, Oda M, Hutter CM, Edwards KL, Schellenberg GD, Tsuang DW, Yearout D, Larson EB, Kawakami H.

Mov Disord. 2009 May 15;24(7):1034-41. doi: 10.1002/mds.22514.

18.

The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.

Sen S, West AB.

Antioxid Redox Signal. 2009 Sep;11(9):2167-87. doi: 10.1089/ARS.2009.2430.

19.

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.

Gandhi PN, Chen SG, Wilson-Delfosse AL.

J Neurosci Res. 2009 May 1;87(6):1283-95. doi: 10.1002/jnr.21949. Review.

20.

Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

Biskup S, West AB.

Biochim Biophys Acta. 2009 Jul;1792(7):625-33. doi: 10.1016/j.bbadis.2008.09.015. Epub 2008 Oct 10. Review.

Supplemental Content

Support Center